The real-world health benefits that cystic fibrosis (CF) patients experienced when they started taking Trikafta (elexacaftor/tezacaftor/ivacaftor) during the COVID-19 pandemic were caused by the medication itself rather than lockdown safety precautions, according to a new U.S. study. Because the U.S. Food and Drug Administration approved Trikafta in…